These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
729 related articles for article (PubMed ID: 16338255)
1. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S; Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255 [TBL] [Abstract][Full Text] [Related]
2. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S; Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956 [TBL] [Abstract][Full Text] [Related]
3. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS; Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322 [TBL] [Abstract][Full Text] [Related]
5. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S; Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
9. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL; Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147 [TBL] [Abstract][Full Text] [Related]
10. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943 [TBL] [Abstract][Full Text] [Related]
12. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169 [TBL] [Abstract][Full Text] [Related]
14. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Keltai M; Tonelli M; Mann JF; Sitkei E; Lewis BS; Hawken S; Mehta SR; Yusuf S; Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):312-8. PubMed ID: 17446813 [TBL] [Abstract][Full Text] [Related]
15. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions. Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316 [TBL] [Abstract][Full Text] [Related]
16. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
17. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Mehta SR; Yusuf S; Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254 [TBL] [Abstract][Full Text] [Related]
18. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E; Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504 [TBL] [Abstract][Full Text] [Related]
19. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Lindgren P; Stenestrand U; Malmberg K; Jönsson B Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611 [TBL] [Abstract][Full Text] [Related]
20. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM; Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]